BACKGROUND: In the older population, multimorbidity is common and 'best practice' may invite the prescription of multiple medications. OBJECTIVE: To examine the association between polypharmacy, defined as the concurrent use of five or more prescription or nonprescription medications, and mortality in 12 423 participants aged ≥65 years representative of the older population of England and Wales. METHODS: Data on self-reported medication use, disability and health conditions were collected at baseline in 1991-3. The cohort was followed for up to 18 years with full mortality notification. Cox proportional hazards regression adjusted for age, baseline institutionalization, smoking, disability and health conditions was used to investigate polypharmacy and mortality, stratified by sex. Various methods for modelling the time-varying effect of polypharmacy are presented. RESULTS: A strong independent association between polypharmacy and mortality existed in the short-term (first 2 years) for both men and women. This association remained, although attenuated, in the medium-long term (2-18 years of follow-up) for women, but became non-significant in the longer term for men. CONCLUSIONS: It remains unclear whether polypharmacy is a marker for poor health or is an independent risk factor for mortality. However, polypharmacy strongly predicts adverse outcomes, and multiple medication use should therefore be carefully monitored in the older population.
BACKGROUND: In the older population, multimorbidity is common and 'best practice' may invite the prescription of multiple medications. OBJECTIVE: To examine the association between polypharmacy, defined as the concurrent use of five or more prescription or nonprescription medications, and mortality in 12 423 participants aged ≥65 years representative of the older population of England and Wales. METHODS: Data on self-reported medication use, disability and health conditions were collected at baseline in 1991-3. The cohort was followed for up to 18 years with full mortality notification. Cox proportional hazards regression adjusted for age, baseline institutionalization, smoking, disability and health conditions was used to investigate polypharmacy and mortality, stratified by sex. Various methods for modelling the time-varying effect of polypharmacy are presented. RESULTS: A strong independent association between polypharmacy and mortality existed in the short-term (first 2 years) for both men and women. This association remained, although attenuated, in the medium-long term (2-18 years of follow-up) for women, but became non-significant in the longer term for men. CONCLUSIONS: It remains unclear whether polypharmacy is a marker for poor health or is an independent risk factor for mortality. However, polypharmacy strongly predicts adverse outcomes, and multiple medication use should therefore be carefully monitored in the older population.
Authors: Yuji Okura; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Richard J Rodeheffer Journal: J Clin Epidemiol Date: 2004-10 Impact factor: 6.437
Authors: F Sganga; D L Vetrano; S Volpato; A Cherubini; C Ruggiero; A Corsonello; P Fabbietti; F Lattanzio; R Bernabei; G Onder Journal: J Nutr Health Aging Date: 2014 Impact factor: 4.075
Authors: Sashika Samaranayaka; Robert J Walker; Ari Samaranayaka; Sarah Derrett; John W B Schollum Journal: Drugs Aging Date: 2018-11 Impact factor: 3.923
Authors: Jianhong Che; Kristen C Malecki; Matthew C Walsh; Andrew J Bersch; Vincent Chan; Christine A McWilliams; F Javier Nieto Journal: WMJ Date: 2014-12
Authors: Amanda M Kong; Alexis Pozen; Kathryn Anastos; Elizabeth A Kelvin; Denis Nash Journal: AIDS Patient Care STDS Date: 2019-03 Impact factor: 5.078
Authors: Michael I Ellenbogen; Peiqi Wang; Heidi N Overton; Christine Fahim; Angela Park; William E Bruhn; Jennifer L Carnahan; Amy M Linsky; Seki A Balogun; Martin A Makary Journal: Drugs Aging Date: 2020-01 Impact factor: 3.923